ECSP22093029A - Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf - Google Patents
Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a brafInfo
- Publication number
- ECSP22093029A ECSP22093029A ECSENADI202293029A ECDI202293029A ECSP22093029A EC SP22093029 A ECSP22093029 A EC SP22093029A EC SENADI202293029 A ECSENADI202293029 A EC SENADI202293029A EC DI202293029 A ECDI202293029 A EC DI202293029A EC SP22093029 A ECSP22093029 A EC SP22093029A
- Authority
- EC
- Ecuador
- Prior art keywords
- braf
- treatment
- diseases
- dihydroquinazolinone
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036522P | 2020-06-09 | 2020-06-09 | |
| US202063116204P | 2020-11-20 | 2020-11-20 | |
| US202163175655P | 2021-04-16 | 2021-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22093029A true ECSP22093029A (es) | 2023-02-28 |
Family
ID=76355554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202293029A ECSP22093029A (es) | 2020-06-09 | 2022-12-07 | Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12303509B2 (https=) |
| EP (1) | EP4161907A1 (https=) |
| JP (2) | JP7312335B2 (https=) |
| KR (1) | KR102904179B1 (https=) |
| CN (1) | CN116096710B (https=) |
| AU (1) | AU2021289163B2 (https=) |
| CL (1) | CL2022003326A1 (https=) |
| CO (1) | CO2022017876A2 (https=) |
| CR (1) | CR20220626A (https=) |
| DO (1) | DOP2022000282A (https=) |
| EC (1) | ECSP22093029A (https=) |
| IL (1) | IL298300B1 (https=) |
| MX (1) | MX2022015703A (https=) |
| PE (1) | PE20231651A1 (https=) |
| PY (1) | PY2146661A (https=) |
| TW (2) | TW202426436A (https=) |
| UA (1) | UA130198C2 (https=) |
| UY (1) | UY39261A (https=) |
| WO (1) | WO2021250521A1 (https=) |
| ZA (1) | ZA202212876B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| AU2020403082A1 (en) * | 2019-12-10 | 2022-05-12 | F. Hoffmann-La Roche Ag | New BRAF inhibitors as paradox breakers |
| PH12022551119A1 (en) | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| TW202426436A (zh) * | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| US20250011304A1 (en) * | 2021-12-08 | 2025-01-09 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
| US20230293465A1 (en) * | 2022-03-17 | 2023-09-21 | St. Jude Children’S Research Hospital | Treatment of low-grade glioma with mirdametinib |
| WO2023183470A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024054591A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| WO2025014933A1 (en) * | 2023-07-10 | 2025-01-16 | Northwestern University | Targeting tim-3 in mapk-driven glioma |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025176139A1 (zh) * | 2024-02-20 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种喹唑啉酮衍生物的晶型及其制备方法和应用 |
| WO2026037755A1 (en) * | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | New methylquinazolinone derivatives |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| CA2577275A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| ES2405785T3 (es) | 2005-05-18 | 2013-06-03 | Array Biopharma Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
| JP2009532450A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ アクチボラグ | 化合物 |
| CN101415689A (zh) | 2006-04-05 | 2009-04-22 | 阿斯利康(瑞典)有限公司 | 具有抗癌活性的经取代的喹唑啉 |
| CN101421253A (zh) | 2006-04-18 | 2009-04-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物 |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PT2324008E (pt) | 2008-07-24 | 2012-06-25 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inibidores da proteína quinase |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| AU2017204973A1 (en) | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| EP3684772B1 (en) | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| WO2019071351A1 (en) | 2017-10-12 | 2019-04-18 | Trillium Therapeutics Inc. | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS |
| RU2678455C1 (ru) | 2018-06-01 | 2019-01-29 | Сергей Викторович Леонов | Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство |
| US11661075B2 (en) | 2018-09-11 | 2023-05-30 | NetraDyne, Inc. | Inward/outward vehicle monitoring for remote reporting and in-cab warning enhancements |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PH12022551119A1 (en) | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| AU2020403082A1 (en) * | 2019-12-10 | 2022-05-12 | F. Hoffmann-La Roche Ag | New BRAF inhibitors as paradox breakers |
| TW202426436A (zh) * | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
-
2021
- 2021-06-04 TW TW112143784A patent/TW202426436A/zh unknown
- 2021-06-04 UA UAA202204519A patent/UA130198C2/uk unknown
- 2021-06-04 MX MX2022015703A patent/MX2022015703A/es unknown
- 2021-06-04 PE PE2022002894A patent/PE20231651A1/es unknown
- 2021-06-04 IL IL298300A patent/IL298300B1/en unknown
- 2021-06-04 CN CN202180056068.XA patent/CN116096710B/zh active Active
- 2021-06-04 TW TW110120375A patent/TWI837478B/zh active
- 2021-06-04 AU AU2021289163A patent/AU2021289163B2/en active Active
- 2021-06-04 US US17/338,767 patent/US12303509B2/en active Active
- 2021-06-04 WO PCT/IB2021/054919 patent/WO2021250521A1/en not_active Ceased
- 2021-06-04 KR KR1020237000172A patent/KR102904179B1/ko active Active
- 2021-06-04 CR CR20220626A patent/CR20220626A/es unknown
- 2021-06-04 JP JP2022575381A patent/JP7312335B2/ja active Active
- 2021-06-04 EP EP21731307.1A patent/EP4161907A1/en active Pending
- 2021-06-08 UY UY0001039261A patent/UY39261A/es unknown
- 2021-06-09 PY PY202102146661A patent/PY2146661A/es unknown
-
2022
- 2022-11-25 CL CL2022003326A patent/CL2022003326A1/es unknown
- 2022-11-25 ZA ZA2022/12876A patent/ZA202212876B/en unknown
- 2022-12-07 EC ECSENADI202293029A patent/ECSP22093029A/es unknown
- 2022-12-08 DO DO2022000282A patent/DOP2022000282A/es unknown
- 2022-12-09 CO CONC2022/0017876A patent/CO2022017876A2/es unknown
-
2023
- 2023-07-07 JP JP2023112365A patent/JP2023123854A/ja active Pending
-
2025
- 2025-04-16 US US19/180,762 patent/US20250241915A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230019944A (ko) | 2023-02-09 |
| KR102904179B1 (ko) | 2025-12-26 |
| US12303509B2 (en) | 2025-05-20 |
| PY2146661A (es) | 2022-10-20 |
| PE20231651A1 (es) | 2023-10-17 |
| DOP2022000282A (es) | 2023-03-31 |
| JP2023524910A (ja) | 2023-06-13 |
| BR112022024597A2 (pt) | 2022-12-27 |
| IL298300B1 (en) | 2026-02-01 |
| JP7312335B2 (ja) | 2023-07-20 |
| IL298300A (en) | 2023-01-01 |
| CA3186343A1 (en) | 2021-12-16 |
| US20220288074A1 (en) | 2022-09-15 |
| CN116096710B (zh) | 2025-07-25 |
| TWI837478B (zh) | 2024-04-01 |
| AU2021289163A1 (en) | 2022-12-22 |
| CL2022003326A1 (es) | 2023-02-24 |
| AU2021289163B2 (en) | 2024-05-02 |
| CO2022017876A2 (es) | 2022-12-20 |
| UA130198C2 (uk) | 2025-12-17 |
| US20250241915A1 (en) | 2025-07-31 |
| CN116096710A (zh) | 2023-05-09 |
| NZ795045A (en) | 2025-05-30 |
| ZA202212876B (en) | 2024-10-30 |
| TW202426436A (zh) | 2024-07-01 |
| UY39261A (es) | 2022-01-31 |
| MX2022015703A (es) | 2023-01-24 |
| CR20220626A (es) | 2023-01-23 |
| EP4161907A1 (en) | 2023-04-12 |
| JP2023123854A (ja) | 2023-09-05 |
| TW202214577A (zh) | 2022-04-16 |
| WO2021250521A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22093029A (es) | Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| CL2020001343A1 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| PE20211089A1 (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CL2021001190A1 (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| CR20200148A (es) | Compuestos monobactámicos cromados para el tratamiento de infecciones bacterianas | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| PE20220710A1 (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl) | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| MX2019003492A (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostericos negativos de mg1ur2, composiciones y su uso. | |
| CO2025011377A2 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| CO2021008535A2 (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| PE20241788A1 (es) | Compuestos de uracilo sustituidos en n3 como inhibidores de trpa1 | |
| MX2021003498A (es) | Derivados de indano para el uso en el tratamiento de infeccion bacteriana. | |
| ECSP24038829A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| ECSP12011718A (es) | Utilización de derivados del indol como activadores de nurr-1, para la aplicación en tratamientos de enfermedades como el parkinson | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 |